专家共识(中国)Fleischner 协会 指南
返回首页

指南:Fleischner Society 2017(13)

时间:2021-08-25 23:51来源:www.ynjr.net 作者:杨宁介入医学网
) ( 44 ). Thus, at least one follow-up scan (36 months) is recommended to determine persistence or resolution. For persistent lesions, yearly follow-up for 5 years is recommended to assess stability
) (44). Thus, at least one follow-up scan (3–6 months) is recommended to determine persistence or resolution. For persistent lesions, yearly follow-up for 5 years is recommended to assess stability of the solid component. The recommended end point of 5 years is necessarily somewhat arbitrary, but it is considered reasonable for patients in whom the dimensions and attenuation of a part-solid nodule have remained unequivocally stable over that time period (42).

Figure 12a:

Figure 12a: (a) Transverse 1-mm CT section through the right upper lobe shows a 6-mm part-solid nodule with a solid component (arrow) smaller than 4 mm. (b) Follow-up CT section at 6-month follow-up shows complete resolution, consistent with a benign cause.

Figure 12b:

Figure 12b: (a) Transverse 1-mm CT section through the right upper lobe shows a 6-mm part-solid nodule with a solid component (arrow) smaller than 4 mm. (b) Follow-up CT section at 6-month follow-up shows complete resolution, consistent with a benign cause.

For solitary part-solid nodules with a solid component 6 mm or larger, a short-term follow-up CT scan at 3–6 months should be considered to evaluate for persistence of the nodule. For nodules with particularly suspicious morphology (ie, lobulated margins or cystic components), a growing solid component, or a solid component larger than 8 mm, PET/CT, biopsy, or resection are recommended (grade 1B; strong recommendation, moderate-quality evidence.) Abundant evidence enables us to confirm that the larger the solid component, the greater the risk of invasiveness and metastases. A solid component larger than 5 mm correlates with a substantial likelihood of local invasion (7,43,4554), and this is a threshold criterion in the newly revised T factor staging for adenocarcinoma (Fig 13) (55

顶一下
(0)
0%
踩一下
(0)
0%
------分隔线----------------------------
  • 上一篇:没有了
  • 下一篇:没有了
推荐内容